Vaxxas
Tuesday, June 04, 2024
Company Presentation
![Medical Devices](https://cdn.asp.events/CLIENT_BIO_7BB99CBA_BAD1_B8C8_CF9F25DA29A80CC6/sites/BIOIC-2024/media/icons/seminars/blank.png)
Company Presentation Theater 3
Vaxxas is a privately held biotechnology company focused on enhancing the performance of existing and next-generation vaccines with its proprietary high-density microarray patch (HD-MAP). Vaxxas is targeting initial applications in infectious diseases and oncology.
With success in several completed human clinical trials involving more than 500 participants; additional ongoing Phase I clinical studies for COVID-19 and seasonal influenza; and other vaccine studies targeting pandemic influenza, funded by the United States Biomedical Advanced Research and Development Authority (BARDA), a typhoid vaccine patch study funded by the Wellcome Trust, and a measles and rubella vaccine patch program supported by the Bill and Melinda Gates Foundation, Vaxxas’ HD-MAP vaccine delivery platform is advancing rapidly toward commercialization.
![Vaxxas](https://www.abstractscorecard.com/uploads/Tasks/upload/21754/XDQDGWMO-1804351-1-JPG.jpg)
Company Website:
https://www.vaxxas.com/
Lead Product in Development:
Influenza vaccine administered using high-density microarray patch
Company HQ City
Cambridge
Company HQ State
MA
Company HQ Country
United States
CEO/Top Company Official
David Hoey
Development Phase of Primary Product
Phase I
Primary Speaker